Occipital Nerve Stimulation for Chronic Migraine: ONSTIM Feasibility Study
Author Information
Author(s): Joel R. Saper, David W. Dodick, Stephen D. Silberstein, Sally McCarville, Mark Sun, Peter J. Goadsby
Primary Institution: Michigan Head–Pain and Neurological Institute
Hypothesis
Can occipital nerve stimulation (ONS) provide a safe and effective treatment for intractable chronic migraine?
Conclusion
The results of this feasibility study offer promise and should prompt further controlled studies of ONS in chronic migraine.
Supporting Evidence
- 39% of subjects in the adjustable stimulation group reported a 50% or greater reduction in headache days.
- Lead migration occurred in 24% of subjects.
- No unanticipated adverse device events occurred during the study.
- Subjects experienced migraine for an average of 22 years prior to the study.
- 66% of subjects in the adjustable stimulation group reported satisfaction with treatment at three months.
Takeaway
Doctors tested a new treatment for really bad headaches called occipital nerve stimulation, and it seemed to help some people feel better.
Methodology
A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation in chronic migraine.
Potential Biases
Implanters were unblinded, which could introduce bias in treatment administration.
Limitations
The trial duration was short, complete blinding was difficult, and the preset stimulation might have had a therapeutic benefit.
Participant Demographics
Subjects were predominantly female (80%) with an average age of 43 years and a history of migraine for an average of 22 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website